Orchestra BioMed Holdings (OBIO) Operating Expenses (2021 - 2026)

Orchestra BioMed Holdings (OBIO) has reported Operating Expenses for 6 consecutive years, with $22.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses rose 12.11% year-over-year to $22.2 million; the TTM figure through Mar 2026 stood at $87.7 million (up 22.32% YoY), while the FY2025 annual figure was $85.3 million, up 27.41% from the prior year.
• Operating Expenses fell to $22.2 million in Q1 2026 per OBIO's latest filing, from $24.2 million in the prior quarter.
• Across five years, Operating Expenses topped out at $24.2 million in Q4 2025 and bottomed at $6.0 million in Q1 2022.
• Historically, Operating Expenses has averaged $15.6 million across 5 years, with a median of $15.0 million in 2024.
• Annual changes were most pronounced in 2022 — Operating Expenses surged 17517.86% — and 2026, when it climbed 12.11%.
• Orchestra BioMed Holdings' Operating Expenses stood at $10.9 million in 2022, then rose by 16.58% to $12.7 million in 2023, then soared by 32.86% to $16.9 million in 2024, then soared by 42.72% to $24.2 million in 2025, then decreased by 8.18% to $22.2 million in 2026.
• Business Quant data shows OBIO's Operating Expenses at $22.2 million in Q1 2026, $24.2 million in Q4 2025, and $21.2 million in Q3 2025.